SCHEMBL3528451

SCHEMBL3528451

CSCc1ccc(Br)cc1[N+](=O)[O-]

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S100A4 P26447 1/20 0.42
TRPV1 Q8NER1 1/20 0.42
KDM4E B2RXH2 1/20 0.38
CYP1A2 P05177 2/20 0.37
PDK1 Q15118 1/20 0.37
MAPK1 P28482 2/20 0.36
PKM P14618 1/20 0.36
RAB9A P51151 1/20 0.36
ACHE P22303 1/20 0.36
ALOX5 P09917 1/20 0.36
SNCA P37840 1/20 0.36
LMNA P02545 1/20 0.35
ALOX15 P16050 1/20 0.35
ALOX12 P18054 1/20 0.35
ERN1 O75460 1/20 0.35
ALDH1A1 P00352 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
ABCB1 P08183 1/20 0.34
ABCC1 P33527 1/20 0.34
CYP3A4 P08684 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3526365 0.86 S100A4 (0.44) S100A4TRPV1KDM4ECYP1A2PDK1
SCHEMBL559763 0.82 PDK1 (0.51) S100A4TRPV1KDM4ECYP1A2PDK1
SCHEMBL12727872 0.81 CYP1A2 (0.57) KDM4ECYP1A2MAPK1ALOX5LMNA
SCHEMBL27875769 0.81 S100A4 (0.45) S100A4TRPV1KDM4ECYP1A2PDK1
SCHEMBL4435695 0.79 S100A4 (0.44) S100A4TRPV1KDM4ECYP1A2PDK1
SCHEMBL1199050 0.79 S100A4 (0.46) S100A4TRPV1KDM4ECYP1A2PDK1
SCHEMBL29561732 0.79 S100A4 (0.46) S100A4TRPV1KDM4ECYP1A2PDK1
SCHEMBL18152743 0.79 ALDH1A1 (0.41) S100A4TRPV1KDM4ECYP1A2MAPK1
SCHEMBL961045 0.77 S100A4 (0.45) S100A4TRPV1KDM4ECYP1A2PDK1
SCHEMBL31272132 0.77 S100A4 (0.45) S100A4TRPV1KDM4ECYP1A2PDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180022746-A1 INDAZOLE AND AZAINDAZOLE SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION VANDERBILT UNIVERSITY 2018-01-25 US disclosed
US-7642276-B2 Fused heteroaryl derivatives for use as P38 kinase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2010-01-05 US disclosed
EP-1531812-B1 FUSED HETEROARYL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS IN THE TREATMENT OF I.A. RHEUMATOID ARTHRITIS SMITHKLINE BEECHAM CORP (US) 2007-06-27 EP disclosed
US-20060122221-A1 Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthristis SMITHKLINE BEECHAM CORPORATION 2006-06-08 US disclosed
EP-1531812-A1 FUSED HETEROARYL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS IN THE TREATMENT OF I.A. RHEUMATOID ARTHRISTIS SMITHKLINE BEECHAM CORPORATION (US) 2005-05-25 EP disclosed
WO-2004010995-A1 FUSED HETEROARYL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS IN THE TREATMENT OF I.A. RHEUMATOID ARTHRISTIS SMITHKLINE BEECHAM CORPORATION (US) 2004-02-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180022746-A1 INDAZOLE AND AZAINDAZOLE SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION GRIK4, GRM4, GRIA4 S100A4 1652/4885TRPV1 628/4885KDM4E 990/4885
US-20060122221-A1 Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthristis MAPK7, CNKSR1, MAPK1 S100A4 4047/4885TRPV1 4491/4885KDM4E 4559/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.